Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2651787 | 0.95 | HDAC1 (0.51) | HDAC1LOXL2CA1CA2CYP4A11 | |
| SCHEMBL2659813 | 0.94 | HDAC1 (0.50) | HDAC1LOXL2CA1CA2CYP4A11 | |
| SCHEMBL2659811 | 0.94 | HDAC1 (0.50) | HDAC1LOXL2CA1CA2CYP4A11 | |
| SCHEMBL5070257 | 0.94 | HDAC1 (0.64) | HDAC1LOXL2CA1CA2EPHX1 | |
| SCHEMBL21088372 | 0.92 | HDAC1 (0.67) | HDAC1LOXL2LMNAEPHX1ALDH1A1 | |
| SCHEMBL18172649 | 0.91 | HDAC1 (0.48) | HDAC1LOXL2CA1CA2CYP4A11 | |
| SCHEMBL2653241 | 0.91 | LTA4H (0.50) | HDAC1LOXL2CA1CA2LMNA | |
| SCHEMBL4092949 | 0.91 | ALDH1A1 (0.60) | HDAC1LOXL2CA1CA2CYP4A11 | |
| SCHEMBL2643164 | 0.91 | ALDH1A1 (0.60) | HDAC1LOXL2CA1CA2CYP4A11 | |
| SCHEMBL13266993 | 0.91 | HDAC1 (0.51) | HDAC1LOXL2CA1CA2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4274569-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-116635028-A | Modulators of c-MYC mRNA translation and their use in the treatment of cancer | 艾尼莫生物科技公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20220370431-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2022-11-24 | — | — | US | disclosed |
| WO-2022150316-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022150316-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| EP-2635551-B1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED N-(BENZYL)CYCLOPROPANAMINES BY IMINE HYDROGENATION | BAYER CROPSCIENCE AG (DE) | 2018-05-02 | — | — | EP | disclosed |
| EP-2635551-B1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED N-(BENZYL)CYCLOPROPANAMINES BY IMINE HYDROGENATION | BAYER CROPSCIENCE AG (DE) | 2018-05-02 | — | — | EP | disclosed |
| US-9260378-B2 | Process for the preparation of substituted N-(benzyl)cyclopropanamines by imine hydrogenation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-02-16 | — | — | US | disclosed |
| US-9260378-B2 | Process for the preparation of substituted N-(benzyl)cyclopropanamines by imine hydrogenation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-02-16 | — | — | US | disclosed |
| US-9260378-B2 | Process for the preparation of substituted N-(benzyl)cyclopropanamines by imine hydrogenation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-02-16 | — | — | US | disclosed |
| EP-2635551-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED N-(BENZYL)CYCLOPROPANAMINES BY IMINE HYDROGENATION | Bayer Cropscience AG (DE) | 2013-09-11 | — | — | EP | disclosed |
| US-20130217910-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED N-(BENZYL)CYCLOPROPANAMINES BY IMINE HYDROGENATION | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2013-08-22 | — | — | US | disclosed |
| US-20130217910-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED N-(BENZYL)CYCLOPROPANAMINES BY IMINE HYDROGENATION | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2013-08-22 | — | — | US | disclosed |
| US-20130217910-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED N-(BENZYL)CYCLOPROPANAMINES BY IMINE HYDROGENATION | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2013-08-22 | — | — | US | disclosed |
| WO-2012059585-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED N-(BENZYL)CYCLOPROPANAMINES BY IMINE HYDROGENATION | BAYER CROPSCIENCE AG (DE) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012059585-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED N-(BENZYL)CYCLOPROPANAMINES BY IMINE HYDROGENATION | BAYER CROPSCIENCE AG (DE) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370431-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | HDAC1 2726/4885LOXL2 4330/4885CA1 4879/4885 |
| US-20130217910-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED N-(BENZYL)CYCLOPROPANAMINES BY IMINE HYDROGENATION | DHPS, PNMT, INMT | HDAC1 4024/4885LOXL2 4726/4885CA1 3582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.